Accueil > Publications > Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno...